Biomarin Pharmaceutical Inc - Asset Resilience Ratio
Biomarin Pharmaceutical Inc (BMRN) has an Asset Resilience Ratio of 0.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Biomarin Pharmaceutical Inc's Asset Resilience Ratio has changed over time. Check Biomarin Pharmaceutical Inc (BMRN) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Biomarin Pharmaceutical Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Biomarin Pharmaceutical Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Biomarin Pharmaceutical Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Biomarin Pharmaceutical Inc Industry Peers by Asset Resilience Ratio
Compare Biomarin Pharmaceutical Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Biomarin Pharmaceutical Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Biomarin Pharmaceutical Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.28% | $248.93 Million | $7.59 Billion | +0.49pp |
| 2024-12-31 | 2.79% | $194.86 Million | $6.99 Billion | -1.87pp |
| 2023-12-31 | 4.66% | $318.68 Million | $6.84 Billion | -4.24pp |
| 2022-12-31 | 8.89% | $567.01 Million | $6.38 Billion | +1.79pp |
| 2021-12-31 | 7.11% | $426.60 Million | $6.00 Billion | -0.01pp |
| 2020-12-31 | 7.12% | $416.23 Million | $5.85 Billion | +0.37pp |
| 2019-12-31 | 6.75% | $316.36 Million | $4.69 Billion | -6.59pp |
| 2018-12-31 | 13.33% | $590.33 Million | $4.43 Billion | -3.89pp |
| 2017-12-31 | 17.22% | $797.94 Million | $4.63 Billion | +7.74pp |
| 2016-12-31 | 9.48% | $381.35 Million | $4.02 Billion | +4.23pp |
| 2015-12-31 | 5.24% | $195.58 Million | $3.73 Billion | +2.45pp |
| 2014-12-31 | 2.80% | $69.71 Million | $2.49 Billion | -6.82pp |
| 2013-12-31 | 9.62% | $215.94 Million | $2.24 Billion | -7.61pp |
| 2012-12-31 | 17.23% | $270.21 Million | $1.57 Billion | +5.83pp |
| 2011-12-31 | 11.40% | $148.82 Million | $1.31 Billion | -3.34pp |
| 2010-12-31 | 14.73% | $186.03 Million | $1.26 Billion | +0.18pp |
| 2009-12-31 | 14.56% | $133.51 Million | $917.16 Million | -22.60pp |
| 2008-12-31 | 37.16% | $336.89 Million | $906.70 Million | -6.66pp |
| 2007-12-31 | 43.82% | $357.25 Million | $815.28 Million | +0.73pp |
| 2006-12-31 | 43.09% | $199.69 Million | $463.44 Million | +38.12pp |
| 2005-12-31 | 4.97% | $9.70 Million | $195.30 Million | -10.37pp |
| 2004-12-31 | 15.34% | $35.73 Million | $232.97 Million | -17.80pp |
| 2003-12-31 | 33.14% | $84.95 Million | $256.34 Million | -3.33pp |
| 2002-12-31 | 36.47% | $40.34 Million | $110.62 Million | -32.54pp |
| 2001-12-31 | 69.01% | $118.57 Million | $171.81 Million | +38.24pp |
| 2000-12-31 | 30.77% | $23.67 Million | $76.93 Million | -7.45pp |
| 1999-12-31 | 38.22% | $39.57 Million | $103.55 Million | -- |
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV t… Read more